受控衰减参数与肝硬度测量在非酒精性脂肪性肝病患者中的准确性
本前瞻性横断面研究纳入179例非酒精性脂肪性肝病患者,以肝活检为标准,评估M或XL探头测量的受控衰减参数(CAP)和肝硬度测量(LSM)的诊断准确性。CAP阈值≥345可排除87%(79.4%-92.5%)人群的显著脂肪变;LSM对F≥F3和F=F4的AUROC均为0.98。CAP是排除晚期脂肪变的满意方法,LSM是排除肝纤维化的良好无创标志物。
要点
- CAP阈值≥345可排除87%(79.4%-92.5%)患者的显著脂肪变。
- LSM对F≥F3和F=F4的AUROC均为0.98,准确性最高。
- 纤维化分期是LSM的独立正预测因子(β=2.6,p<0.001)。
诊断标准与关键数值
- CAP阈值≥345可排除87%(79.4%-92.5%)人群的显著脂肪变。
- LSM对F≥F3的AUROC=0.98,对F=F4的AUROC=0.98。
- 多变量线性回归中,纤维化分期为LSM的正预测因子(β=2.6,p<0.001),小叶炎症为负预测因子(β=-0.68,p=0.04),校正CAP和探头类型后无显著影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
We evaluated the diagnostic accuracy of the controlled attenuation parameter (CAP) and liver stiffness measurements (LSM) measured with either an M or XL probe against liver biopsy (LB) in patients with non-alcoholic fatty liver disease (NAFLD). This study was a cross-sectional prospective study that included 179 NAFLD patients. With a cutoff value for CAP ≥345, we can exclude significant steatosis in 87% (79.4%-92.5%) of our population. With respect to the LSM, the highest accuracy was obtained for F ≥ F3 (area under the receiver operating characteristic curve [AUROC] = 0.98) and F = F4 (AUROC = 0.98). In a multivariable linear regression model, significant predictors influencing LSM were fibrosis stage (β = 2.6, p < 0.001) as a positive predictor and lobular inflammation (β = -0.68, p = 0.04) as a negative predictor, without significant influence after adjustment for CAP and probe type. We found that CAP is a satisfactory method for excluding advanced steatosis, while LSM is a good non-invasive marker for the exclusion of fibrosis.
引用
- Mikolasevic I, Domislovic V, Klapan M, et al. Accuracy of Controlled Attenuation Parameter and Liver Stiffness Measurement in Patients with Non-alcoholic Fatty Liver Disease. Ultrasound Med Biol. 2021. PMID: 33358052. doi:10.1016/j.ultrasmedbio.2020.11.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。